Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Receivables (2021 - 2026)

Indivior Pharmaceuticals has reported Receivables over the past 6 years, most recently at $273.0 million for Q1 2026.

  • For Q1 2026, Receivables rose 12.35% year-over-year to $273.0 million; the TTM value through Mar 2026 reached $273.0 million, up 12.35%, while the annual FY2025 figure was $255.0 million, 0.39% changed from the prior year.
  • Receivables for Q1 2026 was $273.0 million at Indivior Pharmaceuticals, up from $255.0 million in the prior quarter.
  • Over five years, Receivables peaked at $273.0 million in Q1 2026 and troughed at $220.0 million in Q4 2022.
  • A 5-year average of $248.8 million and a median of $251.0 million in 2024 define the central range for Receivables.
  • Biggest five-year swings in Receivables: increased 15.91% in 2023 and later decreased 7.34% in 2025.
  • Year by year, Receivables stood at $220.0 million in 2022, then grew by 15.91% to $255.0 million in 2023, then grew by 0.39% to $256.0 million in 2024, then decreased by 0.39% to $255.0 million in 2025, then increased by 7.06% to $273.0 million in 2026.
  • Business Quant data shows Receivables for INDV at $273.0 million in Q1 2026, $255.0 million in Q4 2025, and $259.0 million in Q3 2025.